1. Scrip
  2. >>Business

Allergan Touts Ubrogepant Phase III Success, But Liver Tox Concerns Overhang

 
• By Joseph Haas

Questions loom as to whether Allergan's pair of CGRP antagonists will face the liver toxicity issues that previously plagued oral CGRP drugs. The firm is counting on the migraine therapies to help offset revenues lost to generics.

Profile of a human head with a colorful symbol of neurons in the brain

Allergan PLC tried to focus on the positive Phase III data released for its acute migraine candidate ubrogepant during the firm's quarterly earnings call Feb. 6, but analysts and investors seem concerned about elevated liver enzyme cases seen in the study that Allergan maintains are not drug-related.

The Dublin-headquartered firm unveiled 12% net revenue growth to $4.33bn during the fourth quarter of 2017, to go with full-year sales revenue of $15.94bn, a 9.4% uptick from 2016. Leading the way during the fourth quarter were aesthetic products such as Botox ($228.4m, up 14

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

Lupin CEO On Trump’s Most Favored Nation Policy, Tariffs, Firm’s Five-Year Plan

 
• By Vibha Ravi

Lupin CEO Vinita Gupta speaks on Trump’s most favored nation policy, the Inflation Reduction Act’s “pill penalty” and other developments in the US, a major market for the company. The company also outlines a five-year plan focused on complex generics and technology platforms.

Eisai Forecasts 73% Leqembi Sales Rise In FY25 As Demand Expands

 
• By Mandy Jackson

Eisai spent most of its FY24 earnings call discussing plans for growing sales of Biogen-partnered Alzheimer’s drug Leqembi from JPY44.3bn ($304.1m) to JPY76.5bn ($525.1m) in FY25.

Merck KGaA Braces For Volatility But Does Not Expect Europe To Budge On Pricing

 
• By Andrew McConaghie

Shares are hit as German conglomerate lowers revenue forecast.

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

More from Business

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 
• By Andrew McConaghie

Company surprises investors with Jørgensen's exit but insists its strategy will not change.

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

In Brief: Sanofi Commits $20bn To US R&D And Manufacturing By 2030

 
• By Sushmita Panda

Move by French major aligns with broader industry efforts to localize production amid political pressure, as Trump pushes to onshore manufacturing and hints at easing tariff threats.